Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 6/20 | 0.42 |
| ▸ | SRC | P12931 | 5/20 | 0.42 |
| ▸ | KDR | P35968 | 5/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.42 |
| ▸ | CDK1 | P06493 | 2/20 | 0.42 |
| ▸ | ROS1 | P08922 | 2/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.42 |
| ▸ | CLK2 | P49760 | 2/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.42 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4572206 | 0.82 | SRC (0.47) | RETSRCKDRDYRK3CDK1 | |
| SCHEMBL4572199 | 0.81 | SRC (0.54) | RETSRCKDRDYRK3CDK1 | |
| SCHEMBL4572197 | 0.81 | SRC (0.54) | RETSRCKDRDYRK3CDK1 | |
| SCHEMBL4572200 | 0.81 | SRC (0.54) | RETSRCKDRDYRK3CDK1 | |
| SCHEMBL4572203 | 0.78 | SRC (0.44) | RETSRCKDRDYRK3CDK1 | |
| SCHEMBL868687 | 0.77 | ABL1 (0.58) | RETSRCKDRABL1EGFR | |
| SCHEMBL20162958 | 0.76 | MAP4K4 (0.44) | RETSRCKDRDYRK3RPS6KB1 | |
| SCHEMBL30104023 | 0.73 | SRC (0.48) | RETSRCKDRDYRK3CDK1 | |
| SCHEMBL3832435 | 0.73 | ADK (0.49) | RETSRCKDRDYRK3CDK1 | |
| SCHEMBL27604421 | 0.73 | RET (0.40) | RETSRCKDRDYRK3CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110300589-B | Bicyclic heteroaryl derivatives as CFTR potentiators | 囊性纤维化基金会 | 2023-03-10 | — | — | CN | disclosed |
| EP-3554506-B1 | BYCYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10766904-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766904-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190330219-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | PFIZER INC. | 2019-10-31 | — | — | US | disclosed |
| US-20190330219-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | PFIZER INC. | 2019-10-31 | — | — | US | disclosed |
| EP-3554506-A1 | BYCYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation Therapeutics, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10377762-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2019-08-13 | — | — | US | disclosed |
| US-10377762-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2019-08-13 | — | — | US | disclosed |
| US-10208053-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10208053-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20190016728-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190016728-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190016727-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190016727-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10131670-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180170938-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170938-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170938-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2018112149-A1 | BYCYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATON THERAPEUTICS INC. (US) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377762-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RY2 | RET 990/4885SRC 2560/4885KDR 3071/4885 |
| US-10208053-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RX3 | RET 1625/4885SRC 3243/4885KDR 3567/4885 |
| US-20190330219-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, SLC26A3, P2RY2 | RET 990/4885SRC 2560/4885KDR 3071/4885 |
| US-20190016728-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | RET 835/4885SRC 2852/4885KDR 2700/4885 |
| US-10131670-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, P2RY2, P2RX5 | RET 835/4885SRC 2852/4885KDR 2700/4885 |
| US-20180170938-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | RET 835/4885SRC 2852/4885KDR 2700/4885 |
| US-20190016727-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | RET 835/4885SRC 2852/4885KDR 2700/4885 |
| US-10766904-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RY2 | RET 990/4885SRC 2560/4885KDR 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.